Cargando…

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

INTRODUCTION: Blood‐based Alzheimer's disease (AD) biomarkers provide opportunities for community studies and across ethnic groups. We investigated blood biomarker concentrations in the Washington Heights‐Inwood Columbia Aging Project (WHICAP), a multi‐ethnic community study of aging and dement...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brickman, Adam M., Manly, Jennifer J., Honig, Lawrence S., Sanchez, Danurys, Reyes‐Dumeyer, Dolly, Lantigua, Rafael A., Lao, Patrick J., Stern, Yaakov, Vonsattel, Jean Paul, Teich, Andrew F., Airey, David C., Proctor, Nicholas Kyle, Dage, Jeffrey L., Mayeux, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Featured Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451860/ https://www.ncbi.nlm.nih.gov/pubmed/33580742 http://dx.doi.org/10.1002/alz.12301

Ejemplares similares

Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease
por: Brickman, Adam M., et al.
Publicado: (2022)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease
por: Kalia, Vrinda, et al.
Publicado: (2023)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Risk of Alzheimer’s Disease is Associated with Longitudinal Changes in Plasma Biomarkers in the Multiethnic Washington Heights, Inwood Columbia Aging Project Cohort
por: Gu, Yian, et al.
Publicado: (2023)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Effects of Vascular Risk Factors on the Association of Blood-Based Biomarkers with Alzheimer’s Disease
por: Hoost, SS, et al.
Publicado: (2023)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Long-Term Depression-Inducing Low Frequency Stimulation Enhances p-Tau181 and p-Tau217 in an Age-Dependent Manner in Live Rats
por: Zhang, Yangyang, et al.
Publicado: (2022)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Differences in plasma metabolites related to Alzheimer's disease, APOE ε4 status, and ethnicity
por: Vardarajan, Badri, et al.
Publicado: (2020)

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau
por: Rosenqvist, Nina, et al.
Publicado: (2018)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

Reliability and Validity of Self-Reported Vascular Risk Factors: Hypertension, Diabetes, and Heart Disease, in a Multi-Ethnic Community Based Study of Aging and Dementia
por: Lee, Annie J., et al.
Publicado: (2023)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
por: Thijssen, Elisabeth H., et al.
Publicado: (2020)

Distinct brain pathologies associated with Alzheimer’s disease biomarker-related phospho-tau 181 and phospho-tau 217 in App knock-in mouse models of amyloid-β amyloidosis
por: Hirota, Yu, et al.
Publicado: (2022)

Cerebrospinal Fluid P-Tau(181P): Biomarker for Improved Differential Dementia Diagnosis
por: Struyfs, Hanne, et al.
Publicado: (2015)

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
por: Rauchmann, Boris Stephan, et al.
Publicado: (2021)

Rare Variants Imputation in Admixed Populations: Comparison Across Reference Panels and Bioinformatics Tools
por: Sariya, Sanjeev, et al.
Publicado: (2019)

Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity
por: Honig, Lawrence S., et al.
Publicado: (2023)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2023)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rlvtocjn29oclq6rbahf3so3tf